Become A Featured Company

CFN Media Exclusive Interview with Creso Pharma COO John Griese

Ryan Allway

March 11th, 2019

Exclusive, News, Top Story

The global cannabis industry is projected to hit $150 billion by 2025, according to Grand View Research, driven by the legalization of recreational and medical cannabis across a growing number of jurisdictions. Creso Pharma is positioned well to generate revenues from around the world.

Creso Pharma Inc.(ASX: CPH) recently received a Canadian license to cultivate for its Mernova Medical Facility in Nova Scotia, making it the only ASX-listed company that has 100% ownership of a Canadian licensed producer. The state-of-the-art GMP-ready indoor facility is capable of producing 4,000 kilograms of cannabis per year with the potential to expand to 40,000 kilograms per year over time.

CFN Media recently sat down with Creso Pharma Inc.(ASX: CPH) COO John Griese to discuss the company’s approach and why investors may want to consider the stock as it continues to roll out products into new markets.

CFN Media: Can you please provide our readers with a brief overview of Creso Pharma?

John: Creso Pharma was founded in late 2016. While we are technically an Australian company, as this is where we first raised our seed funding and publicly listed, our operations are based in Zug, Switzerland—a pharmaceutical hotbed located near Zurich.

Our CEO, Dr. Miri Halperin Wernli, founded the company to leverage her 35 years of clinical research and pharmaceutical development experience and create high-quality, safe, and standardized cannabis products. Many of our team members also come from the pharmaceutical industry.

There are many products on the market, but most of them lack quality and critical controls. Our goal is to bring the rigour of pharmaceutical development and manufacturing to the cannabis industry and create products that patients and consumers can trust.

Plick click here to receive an investor presentation and going public alert

CFN Media: Can you discuss the company’s approach to the industry and how it differs from other licensed producers?

John: Creso is unique in that covers several bases.

We have a portfolio of human and pet products that are already generating revenue. In addition to CBD nutraceuticals, we are heavily investing in THC cultivation with global operations across North and South America, Europe, and Southeast Asia.

Whereas most Canadian LPs are only present in Canada with THC products, our universe is significantly larger, targeting both cannabis and non-cannabis markets. The cannabis market is projected to grow to $150B by 2025, but the cannabis and human and pet supplement market is expected to grow to $350B in the same timeframe.

Our playing field is much larger.

CFN Media: Where do you see the industry headed in 2019 and beyond? And, how are you positioning yourself to take advantage of these trends?

John: More and more countries are loosening the strings on cannabis. South Korea and Thailand recently approved use of medical cannabis. This is clearly a signal that south east Asia is becoming more relaxed on the topic. The U.S. just approved the Hemp Farm Act of 2018 that regulates hemp cultivation and its derivatives on a federal basis. Canada also introduced their federal adult use legislation in October 2018 that governs flower and oils, and edible cannabis will enter the market in October 2019.

We aim to take advantage of these global trends and provide investors with diversified exposure to the industry.

Creso Pharma is positioned well in Europe and already has a presence in Southeast Asia. All of the company’s revenues are currently derived from CBD products with patented formulations that are highly effective at delivering medicine. As edible cannabis becomes regulated, our formulations will focus on the effective delivery of THC as well.

Our Colombian operation will harvest its first full crop in early 2020 and will be a source of low cost oil for the international markets and a source of ingredients to our value added products. As mentioned earlier, our Nova Scotia facility received its license to cultivate earlier this year and over half of our capacity is already committed to Terrascend Canada—an agreement that guarantees revenues for Creso Pharma for several years.

Plick click here to receive an investor presentation and going public alert

CFN Media: Why should investors consider Creso Pharma right now?

John: With all the hype in the marketplace, Creso is quietly building a diverse global enterprise. Few companies are currently generating revenue in countries across Europe and South America, and even fewer companies have established proprietary branded products, such as our CBD based nutraceutical products, cannaQIX® and anibidiol®.

Creso is now entering the Canadian market place with committed revenues from flower and oil destined for the Canadian and European medicinal cannabis marketplace.

Revenue is growing very quickly and our major investment in Nova Scotia is starting to pay off. We are now focusing all of our attention on commercial expansion, product development (specifically in the edible space), and bringing Colombia up to speed. Ask investors which other cannabis companies can claim to have what we have… I think they will be surprised.

For more information, visit the company’s website.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading